Mitsubishi Tanabe lands '$940m' revenue boost after Novartis win
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Mitsubishi Tanabe lands '$940m' revenue boost after Novartis win

NovartisCOVER.jpg
Credit: Taljat / Adobe Stock

Paul Hastings led Mitsubishi Tanabe to victory over Novartis at the International Chamber of Commerce

Japanese pharma company Mitsubishi Tanabe has secured an arbitration victory against Novartis at the International Chamber of Commerce, a case related to blockbuster multiple sclerosis drug Gilenya (fingolimod).

According to Mitsubishi Tanabe, a subsidiary of Mitsubishi Chemical Group, the award will see its revenue increase by around $940 million.

The tribunal, which issued the decision on Monday, February 13, denied Novartis’s claims that provisions of a licence controlling royalties that it had to pay to Mitsubishi Tanabe in the US, EU and other jurisdictions were invalid.

Although Mitsubishi had received royalties from Novartis’s Gilenya, which used the Japanese company's patent rights and know-how, it hadn’t recognised those royalties as revenue. This was due to International Financial Reporting Standards 15, which sets out how to report information about revenue and cash flows from contracts with customers.

However, as a result of the ICC's decision, Mitsubishi can now recognise these royalties as revenue.

In a filing with Japan’s Financial Accounting Standards Foundation on Thursday, February 16, Mitsubishi said it was revising its revenue forecast for this quarter by ¥126 billion ($938.4 million) in light of the arbitration win.

The filing said: “The royalties which have not been recognised as revenue … during the arbitration proceedings will all be recognised as revenue in the fourth quarter of the fiscal year ending March 31 2023.”

Mitsubishi also received ¥3 billion in arbitration-related costs from Novartis.

The Swiss pharma company had filed an application for an arbitration against Mitsubishi Tanabe in 2019.

Paul Hastings advised Mitsubishi Tanabe.

more from across site and ros bottom lb

More from across our site

John Keville, partner at Sheppard Mullin, explains how he secured a patent subject matter eligibility victory for his client against GoPro
An IP partner at Womble Bond Dickinson explains how its combination with Lewis Roca will create a fully-rounded litigation and prosecution service
Ronen Speyer of Evalueserve explains why in a competitive business landscape, IP has become a key driver in gaining a competitive advantage
Michael Sharp, who moved to Canadian firm Field Law from Aurora Cannabis in June, said he is enjoying cross-practice collaboration at his new firm
Yasemin Kenaroğlu tells us about setting up ‘IP School’, Turkish coffee, and why IP is like an iceberg
Irena Royzman, who joined Orrick earlier this year, explains how she's collaborated with her new colleagues to address IP policy concerns
Partners at Fenwick explain why they had to be aggressive when helping Lashify win a patent infringement trial
Big law firms are reorganising their IP departments in response to changing client needs and new legal challenges
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Louis-Pierre Gravelle discusses why he didn’t want to be part of the newly acquired Bereskin & Parr and the opportunities he’s eyeing at his new home, Dipchand
Gift this article